{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:32:51Z","timestamp":1787754771127,"version":"build-2784847793"},"reference-count":70,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Uterine carcinosarcomas (UCSs) are rare and aggressive malignancies with limited epidemiological data. This study aims to evaluate the clinical and pathological features and prognostic factors of UCS in a retrospective cohort of 80 patients, contributing to improved management strategies. Methods: We conducted a retrospective analysis of UCS cases treated from 1995 to 2024 at three institutions. Data on demographics, clinical features, histopathology, treatment, and outcomes were collected. Overall survival (OS) and prognostic factors were assessed using Kaplan\u2013Meier and Cox proportional hazards regression analyses. Results: The median age of patients was 66 years, with a median overall survival of 34.5 months. Disease recurrence occurred in 32.5% of cases, with a median disease-free interval of 17.92 months. Age, tumour stage, and size emerged as significant predictors of survival. Stage I\u2013II patients had a significantly better prognosis than those with Stage III\u2013IV (HR = 0.438, p = 0.008). Tumour size &gt;4 cm was associated with increased mortality (HR = 2.154, p = 0.019). Lymphadenectomy was not independently associated with improved survival. Adjuvant chemotherapy, mainly carboplatin and paclitaxel, was administered to 67.5% of patients, achieving a complete response in 66.67%. Conclusions: Tumour stage and age are significant independent predictors of survival in UCS, underscoring the need for early diagnosis and intervention. Tumour size is also crucial in determining prognosis. The role of lymphadenectomy remains uncertain, emphasizing the importance of individualized treatment approaches. Future research should explore molecular profiling to further refine prognostication and therapeutic strategies for this challenging malignancy.<\/jats:p>","DOI":"10.3390\/cancers16233905","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T12:25:42Z","timestamp":1732191942000},"page":"3905","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Uterine Carcinosarcoma (UCS): A Literature Review and Survival Analysis from a Retrospective Cohort Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-0965","authenticated-orcid":false,"given":"Mauro Francesco Pio","family":"Maiorano","sequence":"first","affiliation":[{"name":"Unit of Obstetrics and Gynecology, Department of Interdisciplinary Medicine (DIM), University of Bari \u201cAldo Moro\u201d, Policlinico of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy"},{"name":"Gynecologic Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-372X","authenticated-orcid":false,"given":"Gennaro","family":"Cormio","sequence":"additional","affiliation":[{"name":"Unit of Obstetrics and Gynecology, Department of Interdisciplinary Medicine (DIM), University of Bari \u201cAldo Moro\u201d, Policlinico of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy"},{"name":"Gynecologic Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3158","authenticated-orcid":false,"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-6421","authenticated-orcid":false,"given":"Vera","family":"Loizzi","sequence":"additional","affiliation":[{"name":"Unit of Obstetrics and Gynecology, Department of Interdisciplinary Medicine (DIM), University of Bari \u201cAldo Moro\u201d, Policlinico of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy"},{"name":"Gynecologic Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"470795","DOI":"10.1155\/2011\/470795","article-title":"Uterine carcinosarcomas (malignant mixed m\u00fcllerian tumours): A review with special emphasis on the controversies in management","volume":"2011","author":"Kanthan","year":"2011","journal-title":"Obstet. Gynecol. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2003.12.029","article-title":"Surveillance, Epidemiology, and End Results Analysis of 2677 Cases of Uterine Sarcoma 1989\u20131999","volume":"93","author":"Brooks","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2008.02.026","article-title":"The utility of preoperative endometrial sampling for the detection of uterine sarcomas","volume":"110","author":"Bansal","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_4","first-page":"213","article-title":"Leiomyosarcoma of the ovary: An unusual presentation","volume":"426","author":"Mankin","year":"2004","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2015.03.041","article-title":"Uterine carcinosarcoma: A review of the literature","volume":"137","author":"Cantrell","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ygyno.2009.10.053","article-title":"The impact of multi-modal therapy on survival for uterine carcinosarcomas","volume":"116","author":"Terstriep","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1999.5681","article-title":"Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: Evidence for monoclonal origin","volume":"76","author":"Sonoda","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ijgo.14033","article-title":"Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival","volume":"158","author":"Raffone","year":"2022","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijgo.13937","article-title":"Prognostic value of the TCGA molecular classification in uterine carcinosarcoma","volume":"158","author":"Travaglino","year":"2022","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103369","DOI":"10.1016\/j.critrevonc.2021.103369","article-title":"Uterine carcinosarcoma: An overview","volume":"163","author":"Pezzicoli","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s10038-021-00940-y","article-title":"Genomic alterations in gynecological malignancies: Histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms","volume":"66","author":"Mori","year":"2021","journal-title":"J. Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa1013961","article-title":"Adverse health outcomes in women exposed in utero to diethylstilbestrol","volume":"365","author":"Hoover","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004347-199004000-00004","article-title":"Prognostic factors for malignant mixed m\u00fcllerian tumors of the uterus","volume":"9","author":"Schweizer","year":"1990","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/01.AOG.0000255980.88205.15","article-title":"Prognostic factors for uterine cancer in reproductive-aged women","volume":"109","author":"Lee","year":"2007","journal-title":"Obstet. Gynecol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1514010","article-title":"Endometrial Cancer","volume":"383","author":"Lu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2021.05.003","article-title":"Uterine carcinosarcomas: From pathology to practice","volume":"162","author":"Toboni","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/ijgc-2021-003178","article-title":"European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ygyno.2020.10.043","article-title":"Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity","volume":"160","author":"Matsuzaki","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jcp.55.5.321","article-title":"Malignant biphasic uterine tumours: Carcinosarcomas or metaplastic carcinomas?","volume":"55","author":"McCluggage","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2005.04.027","article-title":"Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer","volume":"98","author":"Amant","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/ijgc-2022-004073","article-title":"Endometrial carcinosarcoma","volume":"33","author":"Bogani","year":"2023","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1055\/a-1545-4279","article-title":"2020 WHO Classification of Female Genital Tumors","volume":"81","author":"Brambs","year":"2021","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4103\/0973-1482.138197","article-title":"Review literature on uterine carcinosarcoma","volume":"10","author":"Singh","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Op\u0142awski, M., Nowakowski, R., \u015arednicka, A., Ochnik, D., Grabarek, B.O., and Boro\u0144, D. (2021). Molecular Landscape of the Epithelial-Mesenchymal Transition in Endometrioid Endometrial Cancer. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071520"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., and Shen, R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373.","DOI":"10.1038\/nature12113"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/PAS.0000000000001353","article-title":"Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis","volume":"43","author":"Saijo","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/PGP.0000000000000662","article-title":"Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases","volume":"40","author":"Jones","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1610013","DOI":"10.3389\/pore.2021.1610013","article-title":"Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel","volume":"27","author":"Kobayashi","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ygyno.2022.04.014","article-title":"Molecular profiles of endometrial cancer tumors among Black patients","volume":"166","author":"Wilhite","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Yashar","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fan, M.S., Qiu, K.X., Wang, D.Y., Wang, H., Zhang, W.W., and Yan, L. (2024). Risk factors associated with false negative rate of sentinel lymph node biopsy in endometrial cancer: A systematic review and meta-analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1391267"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1245\/s10434-015-4612-2","article-title":"Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping","volume":"23","author":"Schiavone","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2022.02.012","article-title":"Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma","volume":"165","author":"Zammarrelli","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): A multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jamasurg.2020.5060","article-title":"Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging","volume":"156","author":"Cusimano","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.3802\/jgo.2021.32.e60","article-title":"Sentinel lymph Node mapping versus systematic pelvic lymphadenectomy on the prognosis for patients with intermediate-high-risk Endometrial Cancer confined to the uterus before surgery: Trial protocol for a non-inferiority randomized controlled trial (SNEC trial)","volume":"32","author":"Guan","year":"2021","journal-title":"J. Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/ijgc-2022-003378","article-title":"Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: An open-label, non-inferiority, randomized trial (ALICE trial)","volume":"32","author":"Baiocchi","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/ijgc-2021-003029","article-title":"A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer\u2014ENDO-3: ANZGOG trial 1911\/2020","volume":"31","author":"Obermair","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ijgc-2021-002703","article-title":"Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)","volume":"31","author":"Emons","year":"2021","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100930","DOI":"10.1016\/j.gore.2022.100930","article-title":"Patterns of adjuvant treatment and survival outcomes in stage I uterine carcinosarcoma","volume":"39","author":"Cory","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hamoud, B.H., Sima, R.M., Vacaroiu, I.A., Georgescu, M.T., Bobirca, A., Gaube, A., Bobirca, F., and Georgescu, D.E. (2023). The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review. Life, 13.","DOI":"10.3390\/life13071502"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijgo.2008.12.008","article-title":"FIGO staging for uterine sarcomas","volume":"104","author":"Prat","year":"2009","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_46","unstructured":"IBM Corp (IBM SPSS Statistics for Windows, 2016). IBM SPSS Statistics for Windows, Version 24.0."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric Estimation from Incomplete Observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables (with discussion)","volume":"34","author":"Cox","year":"1972","journal-title":"J. Roy. Stat. Soc. Ser. B"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2008.05.016","article-title":"Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: A SEER analysis","volume":"111","author":"Nemani","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cjp2.18","article-title":"In-depth molecular profiling of the biphasic components of uterine carcinosarcomas","volume":"1","author":"McConechy","year":"2015","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jfma.2021.04.016","article-title":"Adjuvant therapy and prognosis in uterine carcinosarcoma","volume":"120","author":"Chiang","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ygyno.2007.07.070","article-title":"A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus","volume":"107","author":"Wolfson","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.21.02050","article-title":"Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial","volume":"40","author":"Powell","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: A Gynecologic Oncology Group Study","volume":"3","author":"Omura","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated Molecular Characterization of Uterine Carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0360-3016(03)01561-X","article-title":"Malignant mixed M\u00fcllerian tumors of the uterus: Analysis of patterns of failure, prognostic factors, and treatment outcome","volume":"58","author":"Callister","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.3802\/jgo.2018.29.e88","article-title":"Clinical utility of CA-125 in the management of uterine carcinosarcoma","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2007.08.060","article-title":"Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma","volume":"107","author":"Huang","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Terblanche, L., and Botha, M.H. (2022). Uterine carcinosarcoma: A 10-year single institution experience. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0271526"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13193-012-0206-7","article-title":"Carcinosarcoma of the uterus\u2014A single institution retrospective analysis of the management and outcome and a brief review of literature","volume":"4","author":"Anupama","year":"2013","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_61","first-page":"e10283","article-title":"Carcinosarcoma of the Uterus: A Study From the Surveillance Epidemiology and End Result (SEER) Database","volume":"12","author":"Nama","year":"2020","journal-title":"Cureus"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2016.04.025","article-title":"Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis","volume":"142","author":"Gonzalez","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/CCO.0b013e328349a45b","article-title":"Uterine carcinosarcoma","volume":"23","author":"Arend","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.3802\/jgo.2020.31.e27","article-title":"Prognostic significance of lymphovascular space invasion in patients with endometrioid endometrial cancer: A retrospective study from a single center","volume":"31","author":"Dai","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/PGP.0b013e31827fedef","article-title":"AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma","volume":"32","author":"Saglam","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ygyno.2006.11.001","article-title":"Uterine carcinosarcoma: Immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets","volume":"105","author":"Cimbaluk","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: Tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7150\/jca.90236","article-title":"WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses","volume":"15","author":"Li","year":"2024","journal-title":"J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Colombo, I., Karakasis, K., Suku, S., and Oza, A.M. (2023). Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery. Cancers, 15.","DOI":"10.3390\/cancers15123220"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ijgc-2022-003614","article-title":"Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: A systematic review and meta-analysis","volume":"32","author":"Maiorano","year":"2022","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/3905\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:37:06Z","timestamp":1760114226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/3905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":70,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16233905"],"URL":"https:\/\/doi.org\/10.3390\/cancers16233905","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}